SARS-CoV-2 vaccine effectiveness trumps immunogenicity in solid organ transplant recipients.

Published on Jul 1, 2021in American Journal of Transplantation7.338
· DOI :10.1111/AJT.16744
Sherif B. Mossad25
Estimated H-index: 25
(Cleveland Clinic)
Sources
Abstract
On June 8th , Malinis et al, published their preliminary observations of the SARS-CoV-2 vaccine effectiveness in solid organ transplant recipients (SOTR) in the AJT (1). Their timely, real world results based on current practices are reassuring. Several studies have now shown 100% effectiveness of multiple SARS-CoV-2 vaccines in preventing hospitalization and death. As of May 17th , 2021, 860 of 123 million (0.0008%) who were fully vaccinated developed breakthrough infections that required hospitalization or were fatal.
References4
Newest
#1Laith J. Abu-Raddad (Cornell University)H-Index: 67
#2Hiam Chemaitelly (Cornell University)H-Index: 21
Last. Adeel A. Butt (Hamad Medical Corporation)H-Index: 57
view all 3 authors...
Efficacy of the BNT162b2 mRNA Vaccine in Qatar As of March 31, 2021, more than 265,000 people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing indicated that 50.0% of infe...
138 CitationsSource
#1Maricar Malinis (Yale University)H-Index: 11
#2Elizabeth Cohen (Yale University)H-Index: 3
Last. Marwan M. Azar (Yale University)H-Index: 20
view all 3 authors...
The COVID-19 pandemic has disproportionately impacted immunosuppressed patients, including solid organ transplant recipients (SOTR). COVID-19-associated mortality among SOTR was estimated at 20.5% in the early phase of the pandemic(1). SARS-CoV-2 vaccination may help reduce the morbidity and mortality of COVID-19 among SOTR. Under emergency use authorization, the US Food Drug Administration approved two SARS-CoV-2 messenger RNA vaccines [BNT162b2 (Pfizer), mRNA-1273 (Moderna)] and an adenovirus ...
3 CitationsSource
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Using prospective cohorts of health care personnel, first respond...
151 CitationsSource
There has been an immense amount of tangential discussion regarding the potential usefulness of serologic testing for COVID-19. Serologic testing has never been routinely used for diagnosing infections with “respiratory viruses” such as influenzae, parainfluenzae, respiratory syncytial viruses,
3 CitationsSource
Cited By1
Newest